LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

Kodu・Aktsiate loetelu・Lantheus Holdings Inc

Lantheus Holdings Inc

Suletud

SektorTervishoid

96.79 0.46

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

94.39

Max

96.87

Põhinäitajad
By Trading Economics
Sissetulek	64M 118M
Müük	-29M 377M
P/E Sektori keskmine	22.451 51.415
Aktsiakasum	1.46
Kasumimarginaal	31.383
Töötajad	1,193
EBITDA	-17M 81M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+7.04% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	410M 6.1B
Eelmine avamishind	96.33
Eelmine sulgemishind	96.79

Uudiste sentiment

By Acuity

19%

81%

41 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

79.24 / 103.64 Toetus ja vastupanu

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. mai 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14. mai 2026, 22:27 UTC

Omandamised, ülevõtmised, äriostud

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14. mai 2026, 22:12 UTC

Tulu

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14. mai 2026, 21:52 UTC

Omandamised, ülevõtmised, äriostud

LVMH to Sell Marc Jacobs

15. mai 2026, 00:00 UTC

Tulu

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14. mai 2026, 23:57 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14. mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14. mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14. mai 2026, 23:47 UTC

Tulu

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14. mai 2026, 23:47 UTC

Tulu

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14. mai 2026, 23:46 UTC

Tulu

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14. mai 2026, 23:46 UTC

Tulu

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14. mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14. mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14. mai 2026, 22:11 UTC

Omandamised, ülevõtmised, äriostud

LVMH Agrees to Sell Marc Jacobs -- WSJ

14. mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14. mai 2026, 22:00 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14. mai 2026, 21:55 UTC

Tulu

Nu Holdings 1Q EPS 18c >NU

14. mai 2026, 21:55 UTC

Tulu

Nu Holdings 1Q Rev $4.97B >NU

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

7.04% tõus

12 kuu keskmine prognoos

Keskmine 103.25 USD 7.04%

Kõrge 115 USD

Madal 90 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Lantheus Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

79.24 / 103.64Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

41 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.